Goresp Digihaler

Goresp Digihaler is a prescription dry‑powder inhaler that delivers a fixed combination of budesonide and formoterol fumarate dihydrate. The inhaler provides inhaled corticosteroid and long‑acting β2‑agonist therapy in a single device, designed for maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD) in the European market. It is intended for regular use as directed by a healthcare professional, according to clinical guidelines and best practice.

Goresp Digihaler is indicated for the long‑term, regular maintenance treatment of two chronic respiratory conditions.

- Asthma maintenance therapy in patients requiring both anti‑inflammatory and bronchodilator effects. - COPD maintenance therapy to reduce exacerbations and improve lung function. - Patients who need a once‑daily inhaled corticosteroid/long‑acting β2‑agonist combination. - Use as part of a comprehensive asthma or COPD management plan that includes trigger avoidance and regular monitoring.

The safety profile of Goresp Digihaler reflects the known effects of inhaled corticosteroids and long‑acting β2‑agonists.

Common: - Hoarseness or throat irritation. - Cough after inhalation. - Oral candidiasis (thrush). - Headache. - Nasal congestion.

Serious: - Paradoxical bronchospasm. - Severe allergic reaction (anaphylaxis). - Decreased bone mineral density with long‑term use. - Glaucoma or cataract progression.

Before prescribing Goresp Digihaler, clinicians should consider several precautionary factors to ensure safe use.

- Assess for active or untreated infections, especially tuberculosis, before initiating therapy. - Monitor patients for signs of oral thrush and advise rinsing mouth after each dose. - Use with caution in patients with a history of cardiovascular disease, arrhythmias, or hypertension. - Evaluate bone health in long‑term users, particularly postmenopausal women. - Consider potential effects on glucose control in diabetic patients. - Avoid abrupt discontinuation; taper if therapy is stopped.

Goresp Digihaler may interact with other medicines that affect the respiratory or cardiovascular systems.

Avoid: - Concomitant use of non‑selective β‑blockers, which can reduce bronchodilator effectiveness. - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) that may increase systemic exposure to budesonide.

Use with caution: - Other inhaled or oral corticosteroids, which can increase risk of systemic steroid effects. - Monoamine oxidase inhibitors or tricyclic antidepressants, which may potentiate β2‑agonist cardiac effects. - Diuretics or antihypertensives, as formoterol can cause transient tachycardia. - Anticholinergic bronchodilators, requiring monitoring for additive airway effects.